Redefining high risk multiple myeloma with an APOBEC/Inflammation-based classifier

Leukemia. 2024 May;38(5):1172-1177. doi: 10.1038/s41375-024-02210-0. Epub 2024 Mar 9.

Sarah Grasedieck^#¹, Afsaneh Panahi^#^{2

3}, Matthew C Jarvis⁴, Faezeh Borzooee^{2

5}, Reuben S Harris^{6

7}, Mani Larijani⁵, Hervé Avet-Loiseau⁸, Mehmet Samur⁹, Nikhil Munshi⁹, Kevin Song¹⁰, Arefeh Rouhi^{2

3}, Florian Kuchenbauer^{11

12}

¹ Department of Microbiology and Immunology, University of British Columbia, 2125 East Mall, Vancouver, BC, Canada.
² Terry Fox Laboratory, BC Cancer Research Institute, Vancouver, BC, Canada.
³ Department of Medicine, University of British Columbia, Vancouver, BC, Canada.
⁴ Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, NC, USA.
⁵ Department of Molecular Biology and Biochemistry, Faculty of Science, Simon Fraser University, Burnaby, BC, Canada.
⁶ Department of Biochemistry and Structural Biology, University of Texas Health San Antonio, San Antonio, TX, USA.
⁷ Howard Hughes Medical Institute, University of Texas Health San Antonio, San Antonio, TX, USA.
⁸ IUCT-Oncopole Toulouse, Toulouse, France.
⁹ Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
¹⁰ Leukemia/Bone Marrow Transplant Program of British Columbia, Vancouver General Hospital, BC Cancer, Vancouver, BC, Canada.
¹¹ Terry Fox Laboratory, BC Cancer Research Institute, Vancouver, BC, Canada. fkuchenbauer@bccrc.ca.
¹² Leukemia/Bone Marrow Transplant Program of British Columbia, Vancouver General Hospital, BC Cancer, Vancouver, BC, Canada. fkuchenbauer@bccrc.ca.

^# Contributed equally.

Abstract